Lancashire and South Cumbria
Formulary
Formulary
5 Infections
For more information about the formulary development process, please see: https://www.lancsmmg.nhs.uk/lancashire-and-south-cumbria-icb-formulary-development/
This chapter of the formulary is under development, please use local/national antimicrobial guidelines to support prescribing choices.
For more information about the formulary development process, please see: https://www.lancsmmg.nhs.uk/lancashire-and-south-cumbria-icb-formulary-development/
The formulary development team can be contacted here: mlcsu.lscformulary@nhs.net
Prescribers must follow the relevant local and national guidance when treating an infection. Some anti-infectives require approval from the local Trust microbiology team for use, consult local guidance for further information.Not all anti-infectives listed in this chapter will be available in all localities; availability will be guided by local need and resistance patterns. |
05-02-04 Echinocandin antifungals
Links
Blackpool Teaching Hospitals: Antimicrobial Formulary- British Association for Sexual Health and HIV
- Central Lancashire/LSCFT/Morecambe Bay Primary Care: NICE Summary of antimicrobial prescribing guidance - managing common infections
- East Lancashire Primary Care: Antimicrobial guide primary care
- East Lancashire Secondary Care: Antimicrobial guide secondary care
- Lancashire Teaching Hospitals Secondary Care: Tap on the bugs app (App store)
- Lancashire Teaching Hospitals Secondary Care: Tap on the bugs app (Google)
- MHRA Drug Safety Update July 2018: Parenteral amphotericin B: reminder of risk of potentially fatal adverse reaction if formulations confused
- MHRA Drug Safety Update July 2020: Liposomal and lipid-complex formulations: name change to reduce medication errors
- MHRA Drug Safety Update Oct 2020: Flucytosine (Ancotil): new contraindication in patients with DPD deficiency
- MHRA Drug Safety Update Sept 2016: Posaconazole (Noxafil): tablets and oral suspension are not directly interchangeable
- MHRA Drug Safety Update:Voriconazole Dec 2014: reminder of risk of liver toxicity, phototoxicity, and squamous cell carcinoma
- MHRA: Flucytosine (Ancotil): new contraindication in patients with DPD deficiency
- MHRA: Liposomal and lipid-complex formulations: name change to reduce medication errors
- MHRA: Miconazole (Daktarin): over-the-counter oral gel contraindicated in patients taking warfarin
- MHRA: Parenteral amphotericin B: reminder of risk of potentially fatal adverse reaction if formulations confused
- MHRA: Posaconazole (Noxafil): tablets and oral suspension are not directly interchangeable
- MHRA: Topical miconazole, including oral gel: reminder of potential for serious interactions with warfarin
- MHRA: Voriconazole: reminder of risk of liver toxicity, phototoxicity, and squamous cell carcinoma
- Mycamine (micafungin) Prescriber Checklist
- NICE CG165: Hepatitis B (chronic): diagnosis and management
- NICE NG120: Cough (acute): antimicrobial prescribing
- NICE NG125: Surgical site infections: prevention and treatment
- NICE NG19: Diabetic foot problems: prevention and management
- NICE NG191: COVID-19 rapid guideline: managing COVID-19
- NICE NG240: Meningitis (bacterial) and meningococcal disease: recognition, diagnosis and management
- NICE NG51: Sepsis: recognition, diagnosis and early management
- NICE NG78: Cystic fibrosis: diagnosis and management
- NPSA alert on injectable amphotericin
- NPSA Rapid response report - Non-lipid and lipid formulations of injectable amphotericin
- University Hospitals of Morecambe Bay: Antimicrobial guide secondary care
- West Lancashire Primary Care: Pan Mersey antimicrobial guide
- WHO: AWaRe classification of antibiotics for evaluation and monitoring of use, 2023